CooperVision to host 4th Asia-Pacific Myopia Management Symposium in Seoul, South Korea

CooperVision, a global leader in myopia management, is proud to announce the 4th Asia-Pacific Myopia Management Symposium (APMMS) will take place in Seoul, South Korea, on October 27, 2024. This groundbreaking event, held in collaboration with the Korean Association of Paediatric Ophthalmology and Strabismus (KAPOS), will convene distinguished eye care professionals, researchers, and industry leaders from around the world to tackle the growing prevalence of myopia in children and foster collaboration across the eye care community.

Themed "Myopia Reframed: Shaping the Future of Eye Health," APMMS 2024 will host a dynamic one-day event expecting over 300 in-person and 1,500 virtual participants. Experts from across the globe, including the Asia-Pacific region, the UK, and the USA, will discuss the latest trends in myopia control. Divided into three insightful sessions, the symposium will explore paradigm shifts in understanding myopia, present cutting-edge strategies for myopia control, and delve into future innovations and the importance of early intervention. The event will showcase research and evidence-based solutions through expert presentations and engaging panel discussions, providing insights into the latest trends and advancements in tackling myopia progression and advancing paediatric eye health.

"Myopia is a progressive and irreversible condition with significant risks if untreated, and its prevalence among young adults in Asia is alarmingly high, exceeding 80% in some regions in APAC. APMMS 2024 aims to enhance the eye care industry's understanding of myopia, its risk to ocular health and sight-threatening conditions in later life and emphasise the urgent need for early intervention" said Kathy Park, President of CooperVision Asia Pacific. "By uniting the foremost experts in the field, our goal is to elevate clinical practices and establish new standards of care that will shape the future of paediatric eye health across the region."

The symposium will highlight key findings from CooperVision's seven-year clinical study on MiSight 1 day, the first FDA-approved soft contact lens proven to slow myopia progression in children. Additionally, it will present results from a ten-year investigator-initiated study, led by Professor Nicola Logan of Aston University, UK, confirming the safety of long-term daily disposable hydrogel soft contact lens wear, MiSight® 1 day.

Dr. Paik Hae-Jung, President of KAPOS and Korean Myopia Society, Gachon University Gil Medical Center, Korea, shared, "South Korea is confronting a pressing myopia epidemic, notably affecting our younger generations. The 4th APMMS offers a pivotal moment for us to join forces with leading eye care professionals to advance our strategies and deepen our understanding of myopia management. We're thrilled to partner with CooperVision in this effort, aligning on a shared vision to elevate and promote myopia management as a cornerstone of paediatric eye care."